Janux Therapeutics Inc. has announced it will host a virtual event on December 1, 2025, to discuss updated clinical data for its investigational drug JANX007. The event will provide an update on Phase 1a dose escalation data and Phase 1b expansion data for JANX007 in adult subjects with metastatic castration-resistant prostate cancer (mCRPC). The results are scheduled to be presented during this event and have not yet been disclosed. JANX007 is a Tumor Activated T Cell Engager (TRACTr) targeting prostate-specific membrane antigen (PSMA) and is currently being evaluated in a Phase 1 clinical trial.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Janux Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251124663993) on November 24, 2025, and is solely responsible for the information contained therein.